Improving therapy of severe infections through drug repurposing of synergistic combinations
Improving therapy of severe infections through drug repurposing of synergistic combinations
复制标题
DOI：
10.1016/j.coph.2019.07.006
复制
发表时间：
2019-10-01
影响因子：
4
通讯作者：
Zheng, Wei
中科院分区：
文献类型：
--
作者：
Cheng, Yu-Shan;Williamson, Peter R.;Zheng, Wei
来自多药耐药（MDR）病原体和新兴病毒的感染对有效的临床治疗提出了挑战。药物再利用和组合筛选可以以传统药物开发方法的一小部分时间和成本提供治疗。两种或三种已知化合物的协同组合可以增加治疗功效并降低单个药物所需的浓度，从而降低药物毒性的风险。使用批准的药物库，在重新利用筛选中识别的传统非抗生素化合物可以快速进入临床试验，因为安全性特征之前已经确定。在此，我们总结了最近的进展，确定协同药物组合和使用药物筛选的个性化药物治疗的MDR病原体和新兴病毒引起的感染。
Infections from multidrug resistant (MDR) pathogens and emerging viruses present challenges for effective clinical treatments. Drug repurposing and combination screens may provide therapies at a fraction of the time and cost of traditional methods of drug development. Synergistic combinations of two or three known compounds can increase therapeutic efficacy and reduce concentrations required for individual drugs, in turn, reducing the risk of drug toxicity. Using libraries of approved drugs, traditionally non-antibiotic compounds identified in repurposing screens can quickly move into clinical trials, since safety profiles have been previously established. Herein we summarize recent advances in identifying synergistic drug combinations and the use of drug screens for personalized medicine treatments of infections caused by MDR pathogens and emerging viruses.